GlassScriptPhysician profile
Jennifer Vazquez
NPI 1598302341
$5,489.73
in general payments reported to CMS, 2019-2025
35 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 93% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $617 · 2022: $947 · 2023: $821 · 2024: $1,547 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,926.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $817.76 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $564.48 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $368.26 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Madrigal Pharmaceuticals | $354.72 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $339.88 | 2021-2025 | |
| Boston Scientific Corporation | $334.02 | 2022-2025 | Spyglass Discover, Watchman Access System |
| Lilly USA, LLC | $309.11 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $222.40 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.86 | 2021-2023 | |
| Kerecis Limited | $190.59 | 2021 | |
| Janssen Pharmaceuticals, INC | $176.85 | 2021-2023 | Xarelto |
| Seqirus USA INC | $160.41 | 2023-2025 | Fluad, Flucelvax, Flucelvax Quadrivalent |
| Smith+Nephew, INC. | $147.19 | 2022 | |
| Viiv Healthcare Company | $130.02 | 2024 | Dovato |
| E.R. Squibb & Sons, L.L.C. | $126.90 | 2024-2025 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $117.12 | 2023-2025 | |
| Edwards Lifesciences Corporation | $114.44 | 2024 | Sapien 3 Ultra Resilia |
| Amgen INC. | $112.74 | 2024-2025 | Evenity, Prolia, Krystexxa |
| Incyte Corporation | $112.10 | 2021 | |
| Exact Sciences Corporation | $101.06 | 2023-2024 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $97.74 | 2023-2024 | |
| Abbvie INC. | $49.88 | 2021-2023 | |
| Dexcom, INC. | $48.92 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $42.25 | 2022-2023 | Veozah |
| Paratek Pharmaceuticals, INC. | $41.53 | 2024-2025 | Nuzyra, Xhance |
| Lucid Diagnostics INC. | $31.90 | 2023 | |
| Ardelyx, INC. | $24.57 | 2024 | Ibsrela |
| Axsome Therapeutics, INC. | $24.53 | 2025 | Auvelity |
| Inspire Medical Systems, INC. | $23.30 | 2023 | Inspire |
| Intuity Medical INC | $19.69 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.80 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $18.45 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.72 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.26 | 2023 | Nuedexta |
| Medicomp INC | $13.28 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Vazquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.